Nipro : Notice on Establishment of US Holding company and Reorganization of Subsidiaries in the Americas

January 11, 2022

NIPRO CORPORATION

Notice on Establishment of US Holding company and

Reorganization of Subsidiaries in the Americas

As stated in the "Notice on Establishment of the Preparatory Office for US Holding company and Reorganization of US Subsidiaries" released on April 1, 2020, Nipro had established a preparatory office for setting up its US Holding company in Miami, Florida, USA, and was working to set up a company that controls our business entities located in the Americas in order to promote further expansion of our global business and enhance regional strategy. We hereby announce that we have established a US Holding company and reorganized our subsidiaries located in the Americas.

1. Purpose of establishing the Holding company and reorganizing subsidiaries

Nipro already has Holding company established in Europe and China. In the United States, we newly established Nipro Holding Americas, Inc. as our US Holding company, with the primary purpose of promoting business development appropriate for local circumstances, swift decision-making, and strengthening the business management system, and reorganized our subsidiaries located in the Americas.

In addition to the above, the new Holding company will integrate fund management of US subsidiaries under its control to improve management efficiency while providing shared services for operations such as accounting and human resources management, helping to optimize operations of the entire Group.

2. Outline of Reorganization of Subsidiaries

1. Outline of reorganization

On August 24, 2021, Nipro Holding Americas (NHA) was established as a wholly owned subsidiary of the Company.

On January 1, 2022, the Company transferred the shares of Nipro Medical Corporation (NMC) and the subsidiaries consolidated under NMC to NHA.

(2) Overview of the Holding company

1. Subsidiaries subject to reorganization [Medical-related business]
2. • Nipro Medical Corporation
   • 1. Established: March 7, 1996
     2. Major shareholder and its ownership ratio: Before transfer: Nipro 100% After transfer: Nipro Holdings Americas 100%
     3. Business outline: Sales of medical devices
     4. Location: Florida, USA
   • Avantec Vascular Corporation
   • 1. Established: December 20, 1999
     2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
     3. Business outline: Development of medical devices
     4. Location: California, USA
   • Infraredx, Inc.
   • 1. Established: November 16, 1999
     2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
     3. Business outline: Manufacture and sales of medical devices
     4. Location: Massachusetts, USA
   • New England Cell Therapeutics, Inc.
   • 1. Established: November 15, 2019
     2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
     3. Business outline: Research and development, manufacturing and sales of regenerative medicine products
     4. Location: Connecticut, USA
   • Nipro Medical Ltda.
   • 1. Established: August 17, 1995
     2. Major shareholder and its ownership ratio: Before transfer: NMC 100%

After transfer: NHA 100%

• 1. Business outline: Manufacture of medical devices
  2. Location: Sao Paulo, Brazil
• Salbego Laboratorio Farmaceutico Ltda.
• 1. Established: June 27, 1989
  2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
  3. Business outline: Manufacture of dialysate
  4. Location: Rio Grande do Sul, Brazil

[Pharma packaging business]

• Nipro PharmaPackaging Americas Corp.
• 1. Established: July 7, 2011
  2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
  3. Business outline: Manufacture and sales of medical glass products
  4. Location: New Jersey, USA

3 Impact on business results

The impact of the transfer of shares, etc. associated with the establishment of the Holding company on the business results for the current fiscal year is insignificant.